Skip to main content
HANGZHOU AGS MEDTECH CO.,LTD logo

HANGZHOU AGS MEDTECH CO.,LTD — Investor Relations & Filings

Ticker · 688581 ISIN · CNE100005ZF0 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 393 across all filing types
Latest filing 2025-06-18 Board/Management Inform…
Country CN China
Listing Shanghai Stock Exchange 688581

About HANGZHOU AGS MEDTECH CO.,LTD

http://www.bioags.com/en/index.aspx

Hangzhou AGS MedTech Co., Ltd. specializes in the research, development, and manufacturing of minimally invasive medical instruments, primarily focusing on endoscopic accessories. The product portfolio encompasses a comprehensive range of disposable devices for gastrointestinal and respiratory interventions, including biopsy forceps, hemoclips, injection needles, polypectomy snares, and guide wires. The company integrates advanced manufacturing processes with rigorous quality management systems, adhering to international standards such as ISO 13485, CE, and FDA. By providing high-precision diagnostic and therapeutic tools, the organization supports clinical procedures in gastroenterology and pulmonology. Its technical expertise facilitates the delivery of reliable solutions aimed at improving procedural outcomes and patient safety in global healthcare markets.

Recent filings

Filing Released Lang Actions
安杰思第三届董事会第二次会议决议公告
Board/Management Information Classification · 95% confidence The document is an announcement of resolutions passed at a board of directors meeting of Hangzhou Anjiesi Medical Technology Co., Ltd. It details the meeting date, attendance, and specific decisions made by the board, such as approval of a restricted stock incentive plan, postponement of certain fundraising projects, and use of foreign exchange funds for project payments. The document does not contain financial statements or detailed financial data but rather reports on board decisions and meeting outcomes. It is not a full annual or interim report, audit report, or earnings release. It is also not a regulatory filing or report publication announcement since it contains substantive content about board decisions. The content fits the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the board or senior management.
2025-06-18 Chinese
安杰思关于部分募投项目延期的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement from Hangzhou Anjiesi Medical Technology Co., Ltd. regarding the delay of certain fundraising investment projects. It details the background of the fundraising, the use of funds, the reasons for the delay, and the approval process by the board and supervisory committee. The document is relatively short (3,715 characters) and focuses on the update about the fundraising project timeline rather than presenting financial statements or comprehensive financial data. It does not contain actual financial results or detailed financial analysis but is an announcement about the status of capital projects funded by the company's fundraising. Therefore, it fits best into the category of Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes.
2025-06-18 Chinese
安杰思2025年限制性股票激励计划授予相关事项的法律意见
Regulatory Filings Classification · 95% confidence The document is a legal opinion issued by a law firm regarding the 2025 restricted stock incentive plan grant matters of Hangzhou Anjiesi Medical Technology Co., Ltd. It details the approval, authorization, grant date, conditions, recipients, price, and quantity of the restricted stock incentive plan. The document is a formal legal opinion rather than a financial report or announcement. It does not contain financial statements or earnings data, nor is it a regulatory announcement or a proxy solicitation. It is a specialized legal opinion related to a stock incentive plan grant, which aligns most closely with a Regulatory Filing (RNS) as it does not fit other specific categories such as Capital/Financing Update or Director's Dealing. The document length is over 6,000 characters and contains substantive content, so it is not a mere announcement of a report publication (RPA). Therefore, the best classification is Regulatory Filings (RNS).
2025-06-18 Chinese
安杰思关于变更保荐代表人的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the change of the sponsor representative for the company's IPO and ongoing supervision. It mentions the replacement of a sponsor representative and confirms that the change does not affect previously issued opinions or documents. The document is short (858 characters) and is an announcement rather than a detailed report or financial statement. It relates to management or board-level information about sponsor representatives but does not announce changes in the company's board or senior management itself. The best fitting category is Regulatory Filings (RNS) as it is a regulatory announcement that does not fit other specific categories like MANG (which is for board or senior management changes) or CAP (capital/financing updates).
2025-06-17 Chinese
安杰思关于2025年限制性股票激励计划内幕信息知情人买卖公司股票情况的自查报告
Director's Dealing Classification · 95% confidence The document is a self-inspection report regarding insider trading activities related to the company's 2025 restricted stock incentive plan. It details the investigation of stock transactions by insiders during a specific period and concludes no insider trading or information leakage occurred. The document is an announcement about insider dealings and compliance with regulations, not a financial report, earnings release, or management report. It fits the category of Director's Dealing (DIRS), which covers reports of personal share transactions by company directors and executives.
2025-06-12 Chinese
安杰思关于完成董事会、监事会换届选举及聘任高级管理人员等事项的公告
Board/Management Information Classification · 95% confidence The document is an official announcement from Hangzhou Anjiesi Medical Technology Co., Ltd. regarding the completion of the board of directors and supervisory board re-election and the appointment of senior management personnel. It details the election results of the board members, supervisory board members, committee members, and the appointment of senior executives such as the general manager, deputy general managers, financial director, and board secretary. The document also includes personal resumes of some senior management and securities affairs representatives. There is no financial data or financial performance report included. The content focuses on changes in the company's board and senior management, which fits the definition of Board/Management Information (MANG). The document length is about 5003 characters, and it is not a brief announcement of a report publication but a substantive announcement of management changes. Therefore, the correct classification is MANG with high confidence.
2025-05-16 Chinese

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.